Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A

被引:5
|
作者
Miyazaki, Yuka [1 ]
Kikuchi, Masaki [2 ]
Umezawa, Koji [3 ]
Descamps, Aurelie [4 ]
Nakamura, Daichi [4 ]
Furuie, Gaku [1 ]
Sumida, Tomoe [4 ,6 ]
Saito, Kanako [1 ]
Kimura, Ninako [1 ]
Niwa, Takashi [4 ]
Sumida, Yuto [4 ,6 ]
Umehara, Takashi [2 ]
Hosoya, Takamitsu [4 ,5 ]
Kii, Isao [1 ,3 ,4 ]
机构
[1] Shinshu Univ, Grad Sch Sci & Technol, Dept Agr, Lab Drug Target Res, 8304 Minami Minowa, Nagano 3994598, Japan
[2] RIKEN, Lab Epigenet Drug Discovery, Ctr Biosyst Dynam Res, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan
[3] Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, 8304 Minami Minowa, Nagano 3994598, Japan
[4] RIKEN, Lab Chem Biol, Ctr Biosyst Dynam Res, Chuo Ku, 6-7-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan
[5] Tokyo Med & Dent Univ TMDU, Inst Biomat & Bioengn, Lab Chem Biosci, Chiyoda Ku, 2-3-10 Kanda Surugadai, Tokyo, Japan
[6] Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan
关键词
DYRK1A; Folding intermediate; Autophosphorylation; FINDY; Alzheimer's disease; Down syndrome; DOWN-SYNDROME CANDIDATE; PROTEIN-KINASE; MOUSE MODEL; MURINE MODEL; DRUG-TARGET; CYCLIN D1; ACTIVATION; AUTOPHOSPHORYLATION; OVEREXPRESSION; REVEALS;
D O I
10.1016/j.ejmech.2021.113948
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
DYRK1A phosphorylates proteins involved in neurological disorders in an intermolecular manner. Meanwhile, during the protein folding process of DYRK1A, a transitional folding intermediate catalyzes the intramolecular autophosphorylation required for the "one-off" inceptive activation and stabilization. In our previous study, a small molecule termed FINDY (1) was identified, which inhibits the folding intermediate-catalyzed intramolecular autophosphorylation of DYRK1A but not the folded state-catalyzed intermolecular phosphorylation. However, the structural features of FINDY (1) responsible for this intermediate-selective inhibition remain elusive. In this study, structural derivatives of FINDY (1) were designed and synthesized according to its predicted binding mode in the ATP pocket of DYRK1A. Quantitative structure-activity relationship (QSAR) of the derivatives revealed that the selectivity against the folding intermediate is determined by steric hindrance between the bulky hydrophobic moiety of the derivatives and the entrance to the pocket. In addition, a potent derivative 3 was identified, which inhibited the folding intermediate more strongly than FINDY (1); it was designated as dp-FINDY. Although dp-FINDY (3) did not inhibit the folded state, as well as FINDY (1), it inhibited the intramolecular autophosphorylation of DYRK1A in an in vitro cell-free protein synthesis assay. Furthermore, dp-FINDY (3) destabilized endogenous DYRK1A in HEK293 cells. This study provides structural insights into the folding intermediate-selective inhibition of DYRK1A and expands the chemical options for the design of a kinase inhibitor. (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Expression and purification of DYRK1A kinase domain in complex with its folding intermediate-selective inhibitor FINDY
    Kimura, Ninako
    Saito, Kanako
    Niwa, Takashi
    Yamakawa, Masato
    Igaue, Shota
    Ohkanda, Junko
    Hosoya, Takamitsu
    Kii, Isao
    PROTEIN EXPRESSION AND PURIFICATION, 2022, 195
  • [2] Selective inhibition of the kinase DYRK1A by targeting its folding process
    Isao Kii
    Yuto Sumida
    Toshiyasu Goto
    Rie Sonamoto
    Yukiko Okuno
    Suguru Yoshida
    Tomoe Kato-Sumida
    Yuka Koike
    Minako Abe
    Yosuke Nonaka
    Teikichi Ikura
    Nobutoshi Ito
    Hiroshi Shibuya
    Takamitsu Hosoya
    Masatoshi Hagiwara
    Nature Communications, 7
  • [3] Selective inhibition of the kinase DYRK1A by targeting its folding process
    Kii, Isao
    Sumida, Yuto
    Goto, Toshiyasu
    Sonamoto, Rie
    Okuno, Yukiko
    Yoshida, Suguru
    Kato-Sumida, Tomoe
    Koike, Yuka
    Abe, Minako
    Nonaka, Yosuke
    Ikura, Teikichi
    Ito, Nobutoshi
    Shibuya, Hiroshi
    Hosoya, Takamitsu
    Hagiwara, Masatoshi
    NATURE COMMUNICATIONS, 2016, 7
  • [4] Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors
    Drung, Binia
    Scholz, Christoph
    Barbosa, Valeria A.
    Nazari, Azadeh
    Sarragiotto, Maria H.
    Schmidt, Boris
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (20) : 4854 - 4860
  • [5] Dyrk1a Inhibition as a treatment for AD
    Dunckley, T.
    Foley, C.
    Hulme, C.
    Velazquez, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 531 - 531
  • [6] Activation, regulation, and inhibition of DYRK1A
    Becker, Walter
    Sippl, Wolfgang
    FEBS JOURNAL, 2011, 278 (02) : 246 - 256
  • [7] DYRK1A and cognition: A lifelong relationship
    Arbones, Maria L.
    Thomazeau, Aurore
    Nakano-Kobayashi, Akiko
    Hagiwara, Masatoshi
    Delabar, Jean M.
    PHARMACOLOGY & THERAPEUTICS, 2019, 194 : 199 - 221
  • [8] Structure-Activity Relationship of PKCβ1 Inhibition by Selective Estrogen Receptor Modulators
    Farmakes, Jasmin
    Bhattacharya, Sayantani Sarkar
    Witter, Taylor L.
    Bruinsma, Elizabeth S.
    Hawse, John R.
    Goetz, Matthew P.
    Schellenberg, Matthew J.
    PROTEIN SCIENCE, 2024, 33 : 198 - 198
  • [9] Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors
    Weber, Csaba
    Sipos, Melinda
    Paczal, Attila
    Balint, Balazs
    Kun, Vilibald
    Foloppe, Nicolas
    Dokurno, Pawel
    Massey, Andrew J.
    Walmsley, David Lee
    Hubbard, Roderick E.
    Murray, James
    Benwell, Karen
    Edmonds, Thomas
    Demarles, Didier
    Bruno, Alain
    Burbridge, Mike
    Cruzalegui, Francisco
    Kotschy, Andras
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (10) : 6745 - 6764
  • [10] Selective Macrocyclic Inhibitors of DYRK1A/B
    Powell, Chelsea E.
    Hatcher, John M.
    Jiang, Jie
    Vatsan, Prasanna S.
    Che, Jianwei
    Gray, Nathanael S.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (04): : 577 - 585